{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:58:55Z","timestamp":1763755135225,"version":"3.45.0"},"reference-count":82,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1188\/18.cjon.s1.5-12","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T11:17:12Z","timestamp":1537528632000},"page":"5-12","source":"Crossref","is-referenced-by-count":8,"title":["Biosimilars: Exploring the History, Science, and Progress"],"prefix":"10.1188","volume":"22","author":[{"given":"Joseph","family":"Tariman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Al-Sabbagh, A., Olech, E., McClellan, J.E., & Kirchhoff, C.F. (2016). Development of biosimilars. Seminars in Arthritis and Rheumatism, 45(5 Suppl.), S11\u2013S18. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.01.002","DOI":"10.1016\/j.semarthrit.2016.01.002"},{"key":"2","unstructured":"Annexton, M.W. (1989). Monoclonal antibodies: A short history. Indiana Medicine, 82, 612\u2013614."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Aschenbrenner, D.S. (2018). FDA offers educational resources on biosimilar and interchangeable products. Amercian Journal of Nursing, 118, 46. https:\/\/doi.org\/10.1097\/01.NAJ.0000530246.60958.50","DOI":"10.1097\/01.NAJ.0000530246.60958.50"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Atkins, M.B. (1997). The treatment of metastatic melanoma with chemotherapy and biologics. Current Opinion in Oncology, 9, 205\u2013213.","DOI":"10.1097\/00001622-199703000-00016"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Baert, F., Noman, M., Vermeire, S., Van Assche, G., D\u2019Haens, G., Carbonez, A., & Rutgeerts, P. (2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. New England Journal of Medicine, 348, 601\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa020888","DOI":"10.1056\/NEJMoa020888"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bartelds, G.M., Krieckaert, C.L., Nurmohamed, M.T., van Schouwenburg, P.A., Lems, W.F., Twisk, J.W., . . . Wolbink, G.J. (2011). Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA, 305, 1460\u20131468. https:\/\/doi.org\/10.1001\/jama.2011.406","DOI":"10.1001\/jama.2011.406"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Beck, M., Michel, B., Rybarczyk-Vigouret, M.C., Leveque, D., Sordet, C., Sibilia, J., & Velten, M. (2017). Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. MAbs, 9, 383\u2013390. https:\/\/doi.org\/10.1080\/19420862.2016.1267087","DOI":"10.1080\/19420862.2016.1267087"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Bennett, C.L., Chen, B., Hermanson, T., Wyatt, M.D., Schulz, R.M., Georgantopoulos, P., . . . Armitage, J.O. (2014). Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncology, 15, e594\u2013e605. https:\/\/doi.org\/10.1016\/S1470-2045(14)70365-1","DOI":"10.1016\/S1470-2045(14)70365-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Blandizzi, C., Meroni, P.L., & Lapadula, G. (2017). Comparing originator biologics and biosimilars: A review of the relevant issues. Clinical Therapeutics, 39, 1026\u20131039. https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.014","DOI":"10.1016\/j.clinthera.2017.03.014"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Bloem, K., Hern\u00e1ndez-Breijo, B., Mart\u00ednez-Feito, A., & Rispens, T. (2017). Immunogenicity of therapeutic antibodies: Monitoring antidrug antibodies in a clinical context. Therapeutic Drug Monitoring, 39, 327\u2013332. https:\/\/doi.org\/10.1097\/FTD.0000000000000404","DOI":"10.1097\/FTD.0000000000000404"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Bourzac, K. (2012). The science of biosimilars. Cancer Discovery, 2, 295. https:\/\/doi.org\/10.1158\/2159-8290.CD-ND2012-017","DOI":"10.1158\/2159-8290.CD-ND2012-017"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Bridges, S.L., Jr., White, D.W., Worthing, A.B., Gravallese, E.M., O\u2019Dell, J.R., Nola, K., . . . Cohen, S.B. (2018). The science behind biosimilars: Entering a new era of biologic therapy. Arthritis and Rheumatology, 70, 334\u2013344. https:\/\/doi.org\/10.1002\/art.40388","DOI":"10.1002\/art.40388"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Brinckerhoff, C.C., & Schorr, K. (2015). Patent watch: Have the biosimilar floodgates been opened in the United States? Nature Reviews Drug Discovery, 14, 303\u2013304. https:\/\/doi.org\/10.1038\/nrd4622","DOI":"10.1038\/nrd4622"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Carbone, P.P. (1990). Progress in the systemic treatment of cancer. Concepts, trials, drugs, and biologics. Cancer, 65, 625\u2013633.","DOI":"10.1002\/1097-0142(19900201)65:3+<625::AID-CNCR2820651305>3.0.CO;2-Y"},{"key":"15","unstructured":"Carver, K.H., Elikan, J., & Lietzan, E. (2010). An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009. Food and Drug Law Journal, 65, 671\u2013818."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Chopra, R., & Lopes, G. (2017). Improving access to cancer treatments: The role of biosimilars. Journal of Global Oncology, 3, 596\u2013610. https:\/\/doi.org\/10.1200\/JGO.2016.008607","DOI":"10.1200\/JGO.2016.008607"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Cohen, H., Beydoun, D. Chien, D., Lessor, T., McCabe, D., Muenzberg, M., . . . Uy, J. (2016). Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Advances in Therapy, 33, 2160\u20132172. https:\/\/doi.org\/10.1007\/s12325-016-0431-5","DOI":"10.1007\/s12325-016-0431-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Colwell, J. (2015). FDA approves first biosimilar, zarxio. Cancer Discovery, 5, 460. https:\/\/doi.org\/10.1158\/2159-8290.CD-ND2015-002","DOI":"10.1158\/2159-8290.CD-ND2015-002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Combe, C., Tredree, R.L., & Schellekens, H. (2005). Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy, 25, 954\u2013962.","DOI":"10.1592\/phco.2005.25.7.954"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Cournoyer, D., Toffelmire, E.B., Wells, G.A., Barber, D.L., Barrett, B.J., Delage, R., . . . Messner, H.A. (2004). Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. Journal of the American Society of Nephrology, 15, 2728\u20132734. https:\/\/doi.org\/10.1097\/01.ASN.0000140219.28618.9F","DOI":"10.1097\/01.ASN.0000140219.28618.9F"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Culliton, B.J. (1972). Biologics division to be transferred from NIH to FDA. Science, 176, 616. https:\/\/doi.org\/10.1126\/science.176.4035.616","DOI":"10.1126\/science.176.4035.616"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Dillman, R.O. (2001). The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Current Pharmaceutical Biotechnology, 2, 293\u2013300.","DOI":"10.2174\/1389201013378617"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Dougherty, M.K., Zineh, I., & Christl, L. (2018). Perspectives on the current state of the biosimilar regulatory pathway in the United States. Clinical Pharmacology and Therapeutics, 103, 36\u201338. https:\/\/doi.org\/10.1002\/cpt.909","DOI":"10.1002\/cpt.909"},{"key":"24","unstructured":"Drugs.com. (2002). FDA launches \u201821st century\u2019 pharmaceutical good manufacturing initiative. Retrieved from http:\/\/www.drugs.com\/news\/fda-launches-21st-century-pharmaceutical-good-..."},{"key":"25","doi-asserted-by":"crossref","unstructured":"Durez, P. (2018). Switching of biologics in RA patients who do not respond to the first biologic. Joint, Bone, Spine, 85, 395\u2013397. https:\/\/doi.org\/10.1016\/j.jbspin.2018.02.001","DOI":"10.1016\/j.jbspin.2018.02.001"},{"key":"26","unstructured":"European Medicines Agency. (2014a). Guidelines on similar biological medicinal products. Retrieved from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guidelin..."},{"key":"27","unstructured":"European Medicines Agency. (2014b). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (Revision 1). Retrieved from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guidelin..."},{"key":"28","unstructured":"European Medicines Agency. (2018). European public assessment reports. Retrieved from https:\/\/bit.ly\/1DYP74U"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Fernandes, G.S., Sternberg, C., Lopes, G., Chammas, R., Gifoni, M.A.C., Gil, R.A., & Araujo, D.V. (2018). The use of biosimilar medicines in oncology\u2014Position statement of the Brazilian Society of Clinical Oncology (SBOC). Brazilian Journal of Medical and Biological Research, 51(3), e7214. https:\/\/doi.org\/10.1590\/1414-431X20177214","DOI":"10.1590\/1414-431x20177214"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Gerrard, T.L., Johnston, G., & Gaugh, D.R. (2015). Biosimilars: Extrapolation of clinical use to other indications. Generics and Biosimilars Initiative Journal, 4, 118\u2013124. https:\/\/doi.org\/10.5639\/gabij.2015.0403.027","DOI":"10.5639\/gabij.2015.0403.027"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Ghosh, P.K. (2017). Similar biologics: Global opportunities and issues. Journal of Pharmacy and Pharmaceutical Sciences, 19, 552\u2013596. https:\/\/doi.org\/10.18433\/J34K6B","DOI":"10.18433\/J34K6B"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Goldsmith, D., Kuhlmann, M., & Covic, A. (2007). Through the looking glass: The protein science of biosimilars. Clinical and Experimental Nephrology, 11, 191\u2013195. https:\/\/doi.org\/10.1007\/s10157-007-0487-2","DOI":"10.1007\/s10157-007-0487-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Hede, K. (2015). First biosimilar drug approved for sale in the United States. Journal of the National Cancer Institute, 107(7), pii: djv191. https:\/\/doi.org\/10.1093\/jnci\/djv191","DOI":"10.1093\/jnci\/djv191"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Holdsworth, S.R., Gan, P.Y., & Kitching, A.R. (2016). Biologics for the treatment of autoimmune renal diseases. Nature Reviews Nephrology, 12, 217\u2013231. https:\/\/doi.org\/10.1038\/nrneph.2016.18","DOI":"10.1038\/nrneph.2016.18"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Hung, A., Vu, Q., & Mostovoy, L. (2017). A systematic review of U.S. biosimilar approvals: What evidence does the FDA require and how are manufacturers responding? Journal of Managed Care and Specialty Pharmacy, 23, 1234\u20131244. https:\/\/doi.org\/10.18553\/jmcp.2017.23.12.1234","DOI":"10.18553\/jmcp.2017.23.12.1234"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Jacobs, I., Singh, E., Sewell, K.L., Al-Sabbagh, A., & Shane, L.G. (2016). Patient attitudes and understanding about biosimilars: An international cross-sectional survey. Patient Preference and Adherence, 10, 937\u2013948. https:\/\/doi.org\/10.2147\/PPA.S104891","DOI":"10.2147\/PPA.S104891"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Koch, R. (1884). An address on cholera and its bacillus. BMJ, 2, 403\u2013407.","DOI":"10.1136\/bmj.2.1235.403"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Koch, R. (1891). A further communication on a remedy for tuberculosis. BMJ, 1, 125\u2013127.","DOI":"10.1136\/bmj.1.1568.125"},{"key":"39","unstructured":"Kuhlik, B.N. (2000). The regulation of drugs and biologics: Fifty years into the future. Food and Drug Law Journal, 55, 21\u201325."},{"key":"40","doi-asserted-by":"crossref","unstructured":"Leach, M.W., Halpern, W.G., Johnson, C.W., Rojko, J.L., MacLachlan, T.K., Chan, C.M., . . . Cavagnaro, J.A. (2010). Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: History, experience, methodology, and future directions. Toxicologic Pathology, 38, 1138\u20131166. https:\/\/doi.org\/10.1177\/0192623310382559","DOI":"10.1177\/0192623310382559"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Leveque, D. (2016). Biosimilar drugs in oncology [Article in French]. Bulletin du Cancer, 103, 294\u2013298. https:\/\/doi.org\/10.1016\/j.bulcan.2015.12.004","DOI":"10.1016\/j.bulcan.2015.12.004"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Lou\u00ebt, S. (2003). Lessons from Eprex for biogeneric firms. Nature Biotechnology, 21, 956\u2013957. https:\/\/doi.org\/10.1038\/nbt0903-956","DOI":"10.1038\/nbt0903-956"},{"key":"43","doi-asserted-by":"crossref","unstructured":"McCamish, M., Pakulski, J., Sattler, C., & Woollett, G. (2015). Toward interchangeable biologics. Clinical Pharmacology and Therapeutics, 97, 215\u2013217. https:\/\/doi.org\/10.1002\/cpt.39","DOI":"10.1002\/cpt.39"},{"key":"44","doi-asserted-by":"crossref","unstructured":"McCamish, M., & Woollett, G. (2012). The state of the art in the development of biosimilars. Clinical Pharmacology and Therapeutics, 91, 405\u2013417. https:\/\/doi.org\/10.1038\/clpt.2011.343","DOI":"10.1038\/clpt.2011.343"},{"key":"45","doi-asserted-by":"crossref","unstructured":"McCamish, M., & Woollett, G.R. (2017). Molecular \u201csameness\u201d is the key guiding principle for extrapolation to multiple indications. Clinical Pharmacology and Therapeutics, 101, 603\u2013605. https:\/\/doi.org\/10.1002\/cpt.616","DOI":"10.1002\/cpt.616"},{"key":"46","unstructured":"McCamish, M., Yoon, W., & McKay, J. (2016). Biosimilars: Biologics that meet patients\u2019 needs and healthcare economics. American Journal of Managed Care, 22(Suppl. 13), S439\u2013S442."},{"key":"47","doi-asserted-by":"crossref","unstructured":"Moore, C. (2017). Biosimilar monoclonal antibodies (mAbs) in oncology. British Journal of Nursing, 26(16), S26\u2013S32. https:\/\/doi.org\/10.12968\/bjon.2017.26.16.S26","DOI":"10.12968\/bjon.2017.26.16.S26"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Moorkens, E., Volto, A.G., Huys, I., Dylst, P., Godman, B., Keuerleber, S., . . . Simoens, S. (2017). Policies for biosimilar uptake in Europe: An overview. PLOS ONE, 12(12), e0190147. https:\/\/doi.org\/10.1371\/journal.pone.0190147","DOI":"10.1371\/journal.pone.0190147"},{"key":"49","unstructured":"Mulcahy, A.W., Hl\u00e1vka, J.P., & Case, S.R. (2017). Biosimilar cost savings in the United States: Initial experience and future potential. Retrieved from https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/perspectives\/PE200\/PE264\/RAND..."},{"key":"50","doi-asserted-by":"crossref","unstructured":"Nabhan, C., & Feinberg, B.A. (2017). Behavioral economics and the future of biosimilars. Journal of the National Comprehensive Cancer Network, 15, 1449\u20131451. https:\/\/doi.org\/10.6004\/jnccn.2017.7023","DOI":"10.6004\/jnccn.2017.7023"},{"key":"51","unstructured":"Nau, J.Y. (2006). Omnitrope, first \u201cbiosimilar\u201d drug of the European Union [Article in French]. Revue Medicale Suisse, 2, 1206."},{"key":"52","doi-asserted-by":"crossref","unstructured":"Nepom, G.T. (2002). Therapy of autoimmune diseases: Clinical trials and new biologics. Current Opinion in Immunology, 14, 812\u2013815.","DOI":"10.1016\/S0952-7915(02)00397-7"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Nowak, A.K., Lake, R.A., Kindler, H.L., & Robinson, B.W. (2002). New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Seminars in Oncology, 29, 82\u201396.","DOI":"10.1053\/sonc.2002.30234"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Pasteur, M. (1881). An address on vaccination in relation to chicken cholera and splenic fever. BMJ, 2, 283\u2013284.","DOI":"10.1136\/bmj.2.1076.283"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Poland, G., & Barrett, A. (2009). The old and the new: Successful vaccines of the 20th century and approaches to making vaccines for the important diseases of the 21st century. Current Opinion in Immunology, 21, 305\u2013307. https:\/\/doi.org\/10.1016\/j.coi.2009.05.014","DOI":"10.1016\/j.coi.2009.05.014"},{"key":"56","unstructured":"Public Health Service Act. (2018). Public Health Service Act [as amended through P.L. 115\u2013180, Enacted June 5, 2018]. Retrieved from https:\/\/legcounsel.house.gov\/Comps\/PHSA-merged.pdf"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Rott, S., & Mrowietz, U. (2005). Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ, 330, 716\u2013720. https:\/\/doi.org\/10.1136\/bmj.330.7493.716","DOI":"10.1136\/bmj.330.7493.716"},{"key":"58","unstructured":"Salmon, D.E. (1886). Recent progress in investigation of hog cholera. Public Health Papers and Reports, 12, 38\u201340."},{"key":"59","doi-asserted-by":"crossref","unstructured":"Schellekens, H. (2004). Biosimilar therapeutic agents: Issues with bioequivalence and immunogenicity. European Journal of Clinical Investigation, 34, 797\u2013799. https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01428.x","DOI":"10.1111\/j.1365-2362.2004.01428.x"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Schiestl, M. (2011). A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products. Biologicals, 39, 297\u2013299. https:\/\/doi.org\/10.1016\/j.biologicals.2011.06.014","DOI":"10.1016\/j.biologicals.2011.06.014"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Schiestl, M., & Krendyukov, A. (2017). The ESMO position paper on biosimilars in oncology: Enhancing the provision of accurate education and information. European Society of Medical Oncology Open, 2(3), e000245. https:\/\/doi.org\/10.1136\/esmoopen-2017-000245","DOI":"10.1136\/esmoopen-2017-000245"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Schiestl, M., Li, J., Abas, A., Vallin, A., Millband, J., Gao, K., . . . Kang, H.N. (2014). The role of the quality assessment in the determination of overall biosimilarity: A simulated case study exercise. Biologicals, 42, 128\u2013132. https:\/\/doi.org\/10.1016\/j.biologicals.2013.11.009","DOI":"10.1016\/j.biologicals.2013.11.009"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Schiestl, M., Zabransky, M., & S\u00f6rgel, F. (2017). Ten years of biosimilars in Europe: Development and evolution of the regulatory pathways. Drug, Design, Development and Therapy, 11, 1509\u20131515. https:\/\/doi.org\/10.2147\/DDDT.S130318","DOI":"10.2147\/DDDT.S130318"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Simard, J.F., Arkema, E.V., Sundstr\u00f6m, A., Geborek, P., Saxne, T., Baecklund, E., . . . Askling, J. (2011). Ten years with biologics: To whom do data on effectiveness and safety apply? Rheumatology, 50, 204\u2013213. https:\/\/doi.org\/10.1093\/rheumatology\/keq326","DOI":"10.1093\/rheumatology\/keq326"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Tabernero, J., Vyas, M., Giuliani, R., Arnold, D., Cardoso, F., Casali, P.G., . . . Ciardiello, F. (2017). Biosimilars: A position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. European Society of Medical Oncology Open, 1(6), e000142. https:\/\/doi.org\/10.1136\/esmoopen-2016-000142","DOI":"10.1136\/esmoopen-2016-000142"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Tanabe, K., Sugimoto, N., & Fujimoto, Y. (2015). A web-based survey to investigate the extent of awareness and understanding for biosimilar among Japanese physicians and pharmacists. Value Health, 18(7), A658. https:\/\/doi.org\/10.1016\/j.jval.2015.09.2381","DOI":"10.1016\/j.jval.2015.09.2381"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Tariman, J.D. (2017). Changes in cancer treatment: Mabs, mibs, mids, nabs, and nibs. Nursing Clinics of North America, 52, 65\u201381. https:\/\/doi.org\/10.1016\/j.cnur.2016.10.004","DOI":"10.1016\/j.cnur.2016.10.004"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Thiel, K.A. (2004). Biomanufacturing, from bust to boom\u2026to bubble? Nature Biotechnology, 22, 1365\u20131372. https:\/\/doi.org\/10.1038\/nbt1104-1365","DOI":"10.1038\/nbt1104-1365"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Thill, M. (2015). New frontiers in oncology: Biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Review of Anticancer Therapy, 15, 331\u2013338. https:\/\/doi.org\/10.1586\/14737140.2015.993318","DOI":"10.1586\/14737140.2015.993318"},{"key":"70","unstructured":"U.S. Food and Drug Administration. (2002). Biologics centennial: 100 years of biologics regulation. Retrieved from https:\/\/www.fda.gov\/downloads\/AboutFDA\/WhatWeDo\/History\/ProductRegulatio..."},{"key":"71","unstructured":"U.S. Food and Drug Administration. (2004). Pharmaceutical cGMPs for the 21st century: A risk-based approach. Retrieved from http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentAprrovalProcess\/Manufactur..."},{"key":"72","unstructured":"U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. Retrieved from https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf"},{"key":"73","unstructured":"U.S. Food and Drug Administration. (2017a). Biosimilar and interchangeable products. Retrieved from https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelope..."},{"key":"74","unstructured":"U.S. Food and Drug Administration. (2017b). Considerations in demonstrating interchangeability with a reference product: Guidance for industry. Retrieved from https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformat..."},{"key":"75","unstructured":"U.S. Food and Drug Administration. (2018a). Biologics Price Competition and Innovation Act of 2009. Retrieved from https:\/\/www.fda.gov\/downloads\/Drugs\/Guid-anceComplianceRegulatoryInforma..."},{"key":"76","unstructured":"U.S. Food and Drug Administration. (2018b). Biosimilar development, review, and approval. Retrieved from https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelope..."},{"key":"77","unstructured":"U.S. Food and Drug Administration. (2018c). Biosimilar product information. Retrieved from https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelope..."},{"key":"78","unstructured":"U.S. Food and Drug Administration. (2018d). Federal Food, Drug, and Cosmetic Act. Retrieved from https:\/\/www.fda.gov\/regulatoryinformation\/lawsenforcedbyfda\/federalfoodd..."},{"key":"79","doi-asserted-by":"crossref","unstructured":"van Overbeeke, E., De Beleyr, B., de Hoon, J., Westhovens, R., & Huys, I. (2017). Perception of originator biologics and biosimilars: A survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs, 31, 447\u2013459. https:\/\/doi.org\/10.1007\/s40259-017-0244-3","DOI":"10.1007\/s40259-017-0244-3"},{"key":"80","doi-asserted-by":"crossref","unstructured":"van Schouwenburg, P.A., Rispens, T., & Wolbink, G.J. (2013). Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nature Review Rheumatology, 9, 164\u2013172. https:\/\/doi.org\/10.1038\/nrrheum.2013.4","DOI":"10.1038\/nrrheum.2013.4"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Willyard, C. (2015). Biosimilar makers flout forced patent negotiations in US. Nature Medicine, 21, 100\u2013101. https:\/\/doi.org\/10.1038\/nm0215-100","DOI":"10.1038\/nm0215-100"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Woollett, G.R. (2012). Innovation in biotechnology: Current and future states. Clinical Pharmacology and Therapeutics, 91, 17\u201320. https:\/\/doi.org\/10.1038\/clpt.2011.219","DOI":"10.1038\/clpt.2011.219"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/22\/5\/supplement\/biosimilars-exploring-history-science-and-progress","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:18Z","timestamp":1763754678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/22\/5\/supplement-october-2018-biosimilars\/biosimilars-exploring-history"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1188\/18.cjon.s1.5-12","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2018,10,1]]}}}